← FDA DRUG APPROVALS

FDA NDA · NDA220295

LYNAVOY

Sponsor: INTERCEPT

APPLICATION
NDA220295
TYPE
NDA
ORIGINAL APPROVAL
2026-03-17
LATEST ACTION
2026-03-17
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LYNAVOY · ReferencePrescription
LINERIXIBAT 40MG · TABLET · ORAL

Approval history

2026-03-17Type 1 - New Molecular Entity · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →